Company Performance - AST SpaceMobile reported a quarterly loss of $0.20 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.17, and compared to a loss of $0.16 per share a year ago, indicating an earnings surprise of -17.65% [1] - The company posted revenues of $0.72 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 82.05%, and this is an increase from year-ago revenues of $0.5 million [2] - Over the last four quarters, AST SpaceMobile has surpassed consensus EPS estimates two times but has not beaten consensus revenue estimates [2] Stock Performance - AST SpaceMobile shares have increased by approximately 22.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.18 on revenues of $7.9 million, and for the current fiscal year, it is -$0.84 on revenues of $57.15 million [7] Industry Outlook - The Wireless Equipment industry, to which AST SpaceMobile belongs, is currently ranked in the top 12% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AST SpaceMobile's stock performance [5]

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -12.90%. A quarter ago, it was expected that this drug developer would post a loss of $0.23 per share when it actually produced a loss of $0.28, delivering a surprise of -21.74%.Over the last four quarters, the company ...

Core Insights - iHeartMedia reported a quarterly loss of $0.63 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.47, and a significant decline from a loss of $0.12 per share a year ago, indicating a surprise of -34.04% [1] - The company generated revenues of $807.1 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 2.19% and showing a slight increase from $799.04 million in the same quarter last year [2] - iHeartMedia's stock has declined approximately 36.4% year-to-date, contrasting with the S&P 500's decline of -3.8% [3] Earnings Outlook - The earnings outlook for iHeartMedia is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.16 on revenues of $907.39 million, and for the current fiscal year at -$0.31 on revenues of $3.71 billion [7] - The company's Zacks Rank is currently 3 (Hold), suggesting that shares are expected to perform in line with the market in the near future [6] Industry Context - The Broadcast Radio and Television industry, to which iHeartMedia belongs, is currently ranked in the top 30% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Topgolf Callaway Brands (MODG) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to earnings of $0.09 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 375%. A quarter ago, it was expected that this maker of golf equipment and accessories would post a loss of $0.40 per share when it actually produced a loss of $0.33, delivering a surprise of 17.5 ...

Stereotaxis Inc. (STXS) came out with a quarterly loss of $0.07 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post a loss of $0.05 per share when it actually produced a loss of $0.09, delivering a surprise of -80%.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.Stereotaxis, which belongs to the Zack ...

分组1 - Arcturus Therapeutics reported a quarterly loss of $0.52 per share, significantly better than the Zacks Consensus Estimate of a loss of $1.58, representing an earnings surprise of 67.09% [1] - The company posted revenues of $29.38 million for the quarter ended March 2025, exceeding the Zacks Consensus Estimate by 3.10%, but down from $38.01 million year-over-year [2] - Over the last four quarters, Arcturus has surpassed consensus EPS estimates three times and topped revenue estimates twice [2] 分组2 - The stock has underperformed, losing about 35.3% since the beginning of the year, compared to a decline of 3.8% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$1.77 on revenues of $21.84 million, and for the current fiscal year, it is -$6.44 on revenues of $96.5 million [7] - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Financial Performance - Quanterix Corporation reported a quarterly loss of $0.53 per share, better than the Zacks Consensus Estimate of a loss of $0.69, but worse than a loss of $0.26 per share a year ago, indicating an earnings surprise of 23.19% [1] - The company posted revenues of $30.33 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.99%, although this is a decline from year-ago revenues of $32.07 million [2] - Over the last four quarters, Quanterix has surpassed consensus revenue estimates three times [2] Stock Performance - Quanterix shares have declined approximately 50.3% since the beginning of the year, compared to a decline of 3.8% for the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is -$0.38 on revenues of $30.83 million, and for the current fiscal year, it is -$1.62 on revenues of $138.32 million [7] Industry Outlook - The Medical - Products industry, to which Quanterix belongs, is currently ranked in the bottom 33% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Quanterix's stock performance [5]

Atlanta Braves Holdings, Inc. (BATRA) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.94. This compares to loss of $0.83 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 29.79%. A quarter ago, it was expected that this company would post a loss of $0.78 per share when it actually produced a loss of $0.31, delivering a surprise of 60.26%.Over the last four quarters, the compa ...

NRG Energy (NRG) came out with quarterly earnings of $2.62 per share, beating the Zacks Consensus Estimate of $1.80 per share. This compares to earnings of $0.80 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 45.56%. A quarter ago, it was expected that this power company would post earnings of $0.95 per share when it actually produced earnings of $1.52, delivering a surprise of 60%.Over the last four quarters, the company has ...

Company Performance - BioXcel Therapeutics reported a quarterly loss of $1.50 per share, significantly better than the Zacks Consensus Estimate of a loss of $2.72, and an improvement from a loss of $13.92 per share a year ago, resulting in an earnings surprise of 44.85% [1] - The company posted revenues of $0.17 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 44%, and down from $0.58 million in the same quarter last year [2] - Over the last four quarters, BioXcel has surpassed consensus EPS estimates four times and topped consensus revenue estimates two times [2] Stock Performance - BioXcel Therapeutics shares have declined approximately 74.4% since the beginning of the year, contrasting with the S&P 500's decline of 3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$2.24 on revenues of $0.4 million, and for the current fiscal year, it is -$16.44 on revenues of $3.51 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which BioXcel belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]